TABLE 1.
Characteristics of excluded studies
| Cochrane review | Study a | Reason(s) for exclusion | ||||
|---|---|---|---|---|---|---|
| Mean age <65 years | Secondary prevention of stroke | Sample size (n < 500) | Non‐English study | No stroke survival curve | ||
| Garrison 16 2017 | JATOS 26 2008 | x | ||||
| VALISH 27 2010 | x | |||||
| Steurer 28 2016 | x | |||||
| Musini 17 2019 |
Carter 29 1970 |
x | ||||
| VA‐II 30 1970 | x | X | x | |||
| HSCSG 31 1974 | x | x | ||||
| ATTMH 32 1981 | x | |||||
| Kuramoto 33 1981 | x | |||||
| Sprackling 34 1981 | X | |||||
| EWPHBPE 35 1989 | x | |||||
| SHEP‐P 36 1989 | x | |||||
| MRC‐TMH 37 1992 | x | |||||
| HYVET P 38 2003 | x | |||||
Abbreviations: ATTMH, Australian therapeutic trial in mild hypertension; EWPHBPE, European working party on high blood pressure in the elderly; HSCSG, hypertension‐stroke cooperative study group; HYVET P, hypertension in the very elderly trial pilot; JATOS, Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients; MRC‐TMH, medical research council trial of treatment of mild hypertension; n, number of participants; SHEP‐P, systolic hypertension in the elderly program pilot; VA‐II, Veterans administration cooperative study group on antihypertensive agents; VALISH, Valsartan in elderly isolated systolic hypertension.
a
Studies are listed chronologically.